推进全球抗生素研究,开发和获取
Laura J V Piddock1, Yewande Alimi2, James Anderson3
1Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland. lpiddock@gardp.org.
Nature medicine
|September 3, 2024
概括
新抗生素的管道不足以对抗日益增加的耐药性感染. 增加公共和慈善资金至关重要,以激励抗生素研发,并确保公平获得治疗.
科学领域:
- * 传染病 传染病
- * 制药研发领域的研发工作.
- * 公共卫生政策 公共卫生政策
背景情况:
- *全球抗药性感染的负担正在增加,超过了新抗生素的开发速度.
- *经济挑战和私人投资下降阻碍了抗生素研发.
- * 抗生素短缺和对治疗的不公平获取是全世界的关键问题.
研究的目的:
- *强调增加对抗生素研发的投资和承诺的必要性.
- *强调公共和慈善资金在解决抗生素耐药性的日益增长的作用.
- * 倡导确保公平获得现有和新型抗生素治疗的政策.
主要方法:
- *分析抗生素研发投资和挑战的现状.
- * 审查新兴的公私伙伴关系和融资模式 (例如,CARB-X,GARDP,AMR行动基金).
- * 审查抗生素的创新性补偿和评估方案.
主要成果:
- * 在新抗生素的需求和目前的研发管道之间存在很大的差距.
- * 公共和慈善倡议在支持抗生素研发方面越来越重要.
- *正在试点实施创新的融资和获取策略,以解决市场失败问题.
结论:
- * 迫切需要全球领导和承诺来加强抗生素研发生态系统.
- * 激励所有部门的公共卫生驱动的研发是必不可少的.
- *确保人人都能获得有效的抗生素必须是全球优先事项.
相关概念视频
00:57Antibiotic Selection
52.4K
Overview
52.4K
01:28International Nursing Organizations II
975
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
975